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¾ ICC  -    Interstitial cells of Cajal 
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PROFORMA I (for H&E) 
Department Of Pathology 
Coimbatore Medical College, Coimbatore. 
Name:         IP no: 
Age:          HPE no:  
Sex:         Ward: 
  
Type of specimen:  Biopsy/ Resected specimen 
Extent of Disease:   SHD/LHD/TCA 
OBSERVER   One / Two 
 
GANGLIONIC SEGMENT: 
x Ganglion cells: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
x Hypertrophic nerve fibres: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
 
AGANGLIONIC SEGMENT: 
x Ganglion cells: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
x Hypertrophic nerve fibres: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
 
Final diagnosis:    HD/ NHD/ Suspicious 
PROFORMA II (for Calretinin IHC) 
Department Of Pathology 
Coimbatore Medical College, Coimbatore. 
Name:         IP no: 
Age:          HPE no:  
Sex:         Ward: 
  
Type of specimen:  Biopsy/ Resected specimen 
Extent of Disease:   SHD/LHD/TCA 
OBSERVER   One / Two 
GANGLIONIC SEGMENT: 
x Ganglion cells: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
Immunoreactivity index:  
x Intrinsic nerve fibres: 
Lamina propria   Present/   absent/   suspicious 
Muscularis mucosa  Present/   absent/   suspicious 
Submucosa    Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
 
AGANGLIONIC SEGMENT: 
x Ganglion cells: 
Submucosa     Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
x Intrinsic nerve fibres: 
Lamina propria   Present/   absent/   suspicious 
Muscularis mucosa  Present/   absent/   suspicious 
Submucosa    Present/   absent/   suspicious 
Muscularis propria   Present/   absent/   suspicious 
 
Final diagnosis:    HD/ NHD/ Suspicious 
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INTRODUCTION 
Hirschsprung’s disease (HD) or aganglionic megacolon is a 
congenital anomaly of innervation of the lower intestine, usually limited 
to the colon, resulting in partial or total functional obstruction [1].  The 
estimated incidence is 1 in 5000 live births [2, 3]. HD is caused by 
congenital absence of the Meissner’s and Auerbach’s autonomic plexus 
(aganglionosis) in the intestinal wall. Disease is usually limited to the 
distal colon (75% of cases) but can involve the entire colon or even the 
entire large and small bowels; the denervated area is always contiguous. 
The etiology of the aganglionosis is thought to be the failure of 
migration of neuroblasts from the neural crest. There is a significant 
genetic component to this disorder at least 12 different genetic mutations 
and many syndromes are associated with HD. 
HD can be suspected clinically by the presenting symptoms, the 
typical appearance of the bowel radiology after contrast enema and by 
measuring recto-anal pressure using rectal manometry. Above all, gold 
standard is the demonstration of the absence of ganglion cells in the 
histopathological sections of rectal biopsy [4]. This helps in arriving at the 
definite diagnosis of HD. 
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Hallmark histological finding is aganglionosis and presence of 
numerous hypertrophic cholinergic nerve fibers [5, 6]. So the suspected 
child usually undergoes suction biopsy or full-thickness biopsy for 
confirmation. Specimen adequacy is very essential for diagnosis of HD in 
routine Hematoxylin & Eosin (H&E) sections. The diagnosis of HD can 
be difficult on H&E alone and requires good experience, principally for 
pathologists who infrequently encounter the disease. H&E has limitations 
in term of examining those submucosal areas where ganglion cells are 
small and irregularly distributed, also difficulty in identifying immature 
ganglion cells of neonates. H&E has shown to have 95% accuracy in HD 
diagnosis. When additional immunohistochemical studies were carried 
out, the correct diagnosis was shown to have very high sensitivity, up to 
99.7% 
[7]
. A number of ancillary methods like enzyme histochemistry 
using Acetylcholinesterase, NADPH-diaphorase etc, and 
immunohistochemistry (IHC) stains like neuron specific enolase (NSE), 
Calretinin, c-kit, S-100 etc. have been studied to overcome these 
limitations and to improve the diagnostic accuracy in specimens. 
Acetylcholinesterase staining can be performed only in frozen sections 
and requires additional specimen for H&E. Among IHC staining studies 
have shown a better diagnostic accuracy with Calretinin. 
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So this study compares the diagnostic sensitivity of H&E and 
Calretinin IHC in suspected cases of HD and the staining pattern of 
ganglion cells in various layers of bowel tissue. Interobserver 
concordance in diagnosis is also evaluated. 
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AIMS & OBJECTIVES 
 
1. To examine the sensitivity of Calretinin 
immunohistochemistry compared to conventional 
Hematoxylin & Eosin (H&E) sections in the diagnosis of 
Hirschsprung disease. 
2. To compare the interobserver concordance in H&E and 
Calretinin immunohistochemistry. 
3. To assess the staining pattern of ganglion cells and nerve 
fibers in both ganglionic and aganglionic segment of bowel. 
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REVIEW OF LITERATURE 
Hirschsprung’s disease (HD) is a common cause of neonatal 
intestinal obstruction. Being a congenital disorder has an incidence   of   1 
in 5000 live births. But it ranges from 1 in 2,000 to 1 in 12,000 live births 
over the world. California Birth Defects Monitoring Program had found 
the highest incidence in Asian populations about 2.8 in 10,000 live births 
[8]. It has been recognized that males are more commonly affected than 
females with a male: female ratio of 4:1 [9, 10, 11]. The neonates usually 
presents with distended abdomen, feeding intolerance with bilious 
aspirates or bilious vomiting and classically with ‘delayed passage of 
meconium’. It has been said that over 90% of HD infants fail to pass 
meconium in the first 24 hours of life [12]. Some children do not become 
obstructed in the neonatal period and present later in infancy or in 
adulthood with severe constipation, chronic abdominal distension and 
failure to thrive [13, 14]. After a careful history and physical examination, 
the diagnostic steps may include radiographic studies, anorectal 
manometry and a rectal biopsy. Of these histopathological examination is 
confirmatory.  
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 HIRSCHSPRUNG’S DISEASE: A HISTORICAL PERSPECTIVE  
Although this condition was initially described by Fredericus 
Ruysch in 1691, Harald Hirschsprung presented the first concise 
description of congenital megacolon in 1886 in his treatise “Constipation 
in newborns due to dilatation and hypertrophy of the colon” [15]. Since 
then many authors have tried to propose specific pathological feature and 
successful treatment for this condition. In 1920, Dalla Valla in their study 
noted aganglionosis in the sigmoid colon of the siblings [16] and in 1940 
Whitehouse and Kernohan demonstrated that the aganglionosis within the 
distal colon or rectum was the cause of the functional obstruction [17] but 
still the origin of the innervation anomaly remained unclear. Bolande in 
the year 1974 used the term neurocristopathy to denote syndromes or 
tumours of neural crest cell origin [18]. The pull-through operational 
procedure was first done by Bill and Swenson in the year 1948. Soave 
and Duhamel developed two and three staged operations for this disease. 
The rectal mucosal biopsy technique was developed by Noblett in the 
year 1969 and this has revolutionised the diagnosis of Hirschsprung’s 
disease [19]. So, along with his co-workers described the procedure for 
pull-through and single staged surgery in 1980. 
 
 
7 
 
 ETIOPATHOGENESIS: 
The basic pathophysiological feature in Hirschsprung’s disease 
(HD) is a functional obstruction caused by a narrowed distal aganglionic 
colonic segment that prevents the propagation of peristaltic waves. 
Failure of neural crest cell migration, genes, cholinergic hyper-
innervation, distributional abnormalities of neurofibrils, disturbance with 
nitric oxide synthetase (NOS) and cajal cell abnormalities all seemed to 
be involved in the pathogenesis of Hirschsprung’s disease. Despite 
extensive research, the complex pathophysiology of HD is not fully 
understood. There is no clear explanation for the occurrence of spastic or 
tonically contracted aganglionic segment of bowel.  
 The Enteric Nervous System (ENS) is the largest and the most 
complex division of the peripheral nervous system plays a crucial role in 
normal gastrointestinal motility. Therefore insights into the embryonic 
origin and development of the ENS are relevant for the understanding of 
the pathophysiology of HD. The ENS contains more neurons than the 
spinal cord and is capable of mediating reflex activity in the absence of 
central nervous system. The ENS is composed of intrinsic neurons, the 
cell bodies and processes that are located inside the bowel wall and 
extrinsic nerve fibres that project into the gut from autonomic and 
sensory ganglia according to Furness JB [20] Although extrinsic 
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innervation modulates the activity of intrinsic neurons, the intrinsic 
neurons are necessary for the complex reflex pathways that ensure 
peristaltic activity. Nerves in both myenteric and submucosal nerve 
plexuses are a mixture of intrinsic and extrinsic fibres and specialized 
enteric glial cells. They project into muscularis propria, muscularis 
mucosa, and lamina propria according to Raj P. Kapur [21].The 
sympathetic and parasympathetic arms of the peripheral nervous system 
and the neurons of the ENS is derived primarily from cells of the vagal 
segment of the neural crest (NC)[22], a part of ectoderm. Problems in NC 
development are the basis of many human syndromes and birth defects 
known collectively as Neurocristopathies. 
Neural crest cells are pluripotent stem cells, the epithelio-
mesenchymal transformation allows NC cells to migrate along pathways 
of defined routes to various tissues, where they stop moving and 
differentiate into various cell types. In the human fetus, neural crest-
derived neuroblasts first appear in the developing esophagus at 5 weeks 
of gestation, and they migrate down in a craniocaudal direction to the 
small intestine by the 7th week and reaches colon during the 12th week of 
gestation [23, 24]. The NC cells first form the myenteric plexus just outside 
the circular muscle layer. The mesenchymally derived longitudinal 
muscle layer then forms, sandwiching the myenteric plexus after it has 
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been formed in the 12th week of gestation. In addition, after the 
craniocaudal migration has ended, the submucous plexus is formed by the 
neuroblasts, which migrate from the myenteric plexus across the circular 
muscle layer and into the submucosa; Normal ganglion cell distribution is 
present at 24 weeks of gestation in humans. These ganglia continue to 
mature on into childhood. 
HD results when the normal migration of neural crest cells fails to 
reach the rectum or sometimes normal cell migration may occur but 
neuroblasts may be subject to apoptosis or there may be failure of 
proliferation, or improper differentiation within the affected distal 
intestinal segment. Fibronectin, laminin, neural cell adhesion molecule 
(NCAM), and neurotrophic factors present in the intestinal stroma are 
necessary for normal enteric ganglion development, whereas their 
absence or dysfunction may also have a role in the etiology of HD[25,26,27]. 
The exact mechanisms underlying neural crest cell migration failure and 
premature death of ganglion cells in HD are still unknown, but complex 
genetic component play a role. 
Gene mutations implicated in the pathogenesis include several 
proteins that modulate this immigration, differentiation and survival of 
the neural crest cells. Butler Tjaden and colleagues reported that 
mutations in the genes - RET, GDNF, GFRα1, NRTN, EDNRB, ET3, 
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ZFHX1B, PHOX2b, SOX10, and SHH are present in approximately 50% 
of HD patients [28]. Some patients with HD show mutations in more than 
one gene. 
RET Proto-oncogene & RET/GDNF/GFRα1 Signaling System:
 
It is a major gene located on chromosome 10 implicated in the 
pathogenesis of HD with heterozygous mutations, found in 50% of  the 
familial cases and 15–20% of isolated cases [28, 29]. Penetrance of the RET 
mutations is incomplete and sex dependent. RET mutation is most 
frequently associated with long segment HD and Total colonic 
aganglionosis. RET/GDNF/GFRα1 signaling pathway is one of the 
primary pathways, which promotes the survival of neurons, mitosis of 
neuronal progenitor cells, and differentiation of neurons and neurite 
extension [30]. RET receptor is the signaling component of receptor 
complexes with four ligands named glial derived neurotropic factor 
(GDNF), neurturin (NTN), artemin (ATM), and persephin (PSP)[23,30] (Fig 
1: A&B). The complete receptor complex includes the RET receptor 
tyrosine kinase and a glycosylphosphatidylinositol- anchored binding 
component (GFRα1-4) [23, 31]. Iwashita et al. noted that the glial cell line-
derived neurotropic factor receptor 
11 
 
 
 
Figure.1: GDNF family ligand (GFL) interaction with their receptors 
(A) a dimer of GDNF brings together two molecules of GRFα1. This 
complex of RET leading to transphosphorylation of their tyrosine kinase 
domains. (B) All GFLs activate RET tyrosine kinase via different GFR 
alpha receptors [33]. 
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(GDNF) RET is necessary for neural crest stem cell migration in the gut 
[32]. Any disturbance of GDNF/GFRα1-mediated signaling leads to the 
failure of ENS development. Mutations involving the RET gene, GDNF 
and its co receptor GFRα1 all are responsible for HD pathogenesis. 
ENDOTHELIN Signaling Pathway: 
The endothelins (EDN1, 2 and 3) are intercellular local messengers 
that act through the cell surface receptors, EDNRA and EDNRB [30]. EDN 
is initially expressed in an immature form. It is processed to an active 
peptide by the enzyme, endothelin converting enzyme 1 (ECE1) [30, 34]. 
EDN3 and EDNRB have a role in the migration and development of the 
ENS. Several studies suggest that the downregulation of EDN3 
expression may play a role in the pathogenesis of Hirschsprung’s disease 
in the sporadic cases [35, 36]. 
SOX10 gene: 
The SOX10 (sex determining region Y-box) gene is a member of 
the SRY-related family of transcription factors. It is expressed in 
neuronal crest derivates that contribute to the formation of the peripheral 
nervous system during embryogenesis [37]. Mutation in SOX10 is 
responsible for distal aganglionosis. There were two phenotypes 
identified PCWH [38] (severe form) and Waardenburg-Shah syndrome 
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type 4 [39, 40] (WS4- milder form) are caused by two distinct molecular 
mechanisms. 
PHOX2b gene: 
Paired - like homeobox 2b gene encodes a transcription factor that 
regulates ret expression and thus it is essential for ENS development [41]. 
Heterozygous mutations cause a complex dysautonomia, associating 
Hirschsprung’s disease, Congenital Central Hypoventilation Syndrome 
(CCHS) and Tumors of the Sympathetic Nervous System (TSNS) in 
various combinations [42]. 
ZFHX1B gene: 
 ZFHX1B (zinc finger homeo domain transcription factor) is also 
known as SMAD interacting protein 1 (SMADIP1/SIP1). The 
observation of a translocation involving the ZFHX1B locus (2q22) in a 
patient with Hirschsprung’s disease is associated with (Mowat-Wilson 
syndrome) syndromic form of Hirschsprung’s disease [43]. 
 Mutations in the other minor genes like KIAA1279, SHH and etc 
also involved in HD pathogenesis. 
 Apart from genetics, Interstitial cells of Cajal, Smooth muscle, 
Pacemaker cells connecting enteric nerves and Extracellular Matrix also 
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play a role in the pathophysiology. It suggests that HD’s pathophysiology 
is not limited to cells normally present within the enteric ganglia, alone. 
ROLE OF ENZYMES IN PATHOGENESIS: 
Nitric Oxide Synthase (NOS) & NADPH - Diaphorase: 
 Nitric oxide is the major inhibitory non-adrenergic non-cholinergic 
neurotransmitter in the gastrointestinal tract that mediates smooth muscle 
relaxation [44]. Nitric oxide is synthesized by the activation of neuronal 
NOS. Increasing number of this nitrergic nerve fibres are seen in the 
circular muscle [45]. NOS is abundant in normal colon and ganglionic 
bowel of HD. In contrast, NOS is selectively absent from the plexus area 
and from the musculature of aganglionic bowel in HD. Many studies 
indicate that there is impaired NO synthesis in the aganglionic bowel in 
HD and this deficiency could prevent smooth muscle relaxation, thereby 
causing the lack of peristalsis in HD [46, 47]. Nicotinamide adenine 
dinucleotide phosphate-diaphorase (NADPH- D) is seen in the same 
location and has been shown to have identical function as that of NOS [48, 
49]. 
Acetyl Choline Esterase (AChE): 
 AChE gene give rise to various forms of acetylcholine esterase. 
Hydrophobic G4 form (AChE-G4)   is seen in differentiating embryonal 
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cells, neural crest cells and   in the synapses of the central nervous 
system.  In HD there is increase in G4 levels of AChE, which was first 
reported in rectal suction biopsies by Boston et al [50]. The reason behind 
why acetylcholine esterase levels are increased in HD is complex. 
Physical stress, psychological stress, or chemical stress, denervation and 
electric activity all can increase AChE. It’s increase correlate with 
hypertrophic nerves. These hypertrophic parasympathetic nerves are 
coarse fibres that develop in muscularis propria and also in the lamina 
propria. AChE activity is the usual marker of cholinergic nerves and has 
become a widely accepted technique for diagnosis of HD. 
Interstitial cells of Cajal (ICC): 
Santiago Ramon y Cajal, a Spanish Nobel Laureate physician and 
neuropathologist, in the year 1893, first described this as the cell located 
between smooth muscle and nerve endings. Based on this location he 
named it as “interstitial”Cells of Cajal. ICCs are modified smooth muscle 
cells and pacemakercells of the GIT. It consists of a thin cytoplasm, a 
nucleus that is large and oval and has dendritic like processes. In HD, 
ICCs, however, are reduced in number and disrupted in pattern, but they 
are not totally absent from the aganglionic region of the colon [51]. 
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 Mast cells (MC) are responsible for various inflammatory 
processes and produce nerve growth factors, there by influencing on the 
clinical course of Hirschsprung's disease. 
SYNDROMES ASSOCIATIED WITH HD: 
I. NEUROCRISTOPATHIES - 
WAARDENBURG SYNDROME TYPE 4: 
 Waardenburg syndrome (WS) is a human genetic condition 
characterized by defective melanocyte function (with pigmentation 
anomalies of the skin, hair and iris), cochlear sensorineural deafness and 
craniofacial abnormalities. It occurs in association with intestinal 
aganglionosis as the uncommon Shah-Waardenburg subtype (WS4). 
Genes implicated are SOX10, EDN3 and EDNRB.  
CONGENITAL CENTRAL HYPOVENTILATION SYNDROME 
(CCHS): 
CCHS or Ondine’s curse is an uncommon syndrome occasionally 
associated with HD (14–20% of cases), as well as with tumors of neural 
origin and autonomic dysfunction HD-CCHS (Haddad’s syndrome). They 
have a heterozygous mutation in RET, EDN3, GDNF, or BDNF. It is 
mostly associated with long-segment aganglionosis. Other features 
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include impaired ventilatory response to hypercarbia and hypoxemia, 
tonic pupil, neuroblastoma, ganglioneuromas and ganglioneuroblastomas. 
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2): 
 It is an autosomal dominant disorder characterized by parathyroid 
hyperplasia, medullary thyroid carcinoma and pheochromocytoma. This 
disease is a result of RET gene mutations and it is associated with 
Hirschsprung’s disease. It increases the cancer disposition in HD 
individuals. 
II. NON NEUROCRISTOPATHIES – 
GOLDBERG-SHPRINTZEN SYNDROME: 
It is an autosomal recessive condition. Hirschsprung’s disease is 
seen in this syndrome along with cleft palate, colocoma, microcephaly, 
facial dysmorphism and mental retardation. 
BARDET-BIEDL SYNDROME: 
 It is a autosomal recessive condition. Features of this syndrome 
include mental retardation, renal abnormalities, progressive pigmentary 
retinopathy, obesity, hypogenitalism, postaxial polydactyly and it is 
associated with Hirschsprung’s disease in about 2% of the individuals. 
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BRESEK/BRESHECK SYNDROME: 
 It is a rare X-linked multiple congenital malformation 
characterized by Brain anomalies, Retardation, Ectodermal dysplasia, 
Skeletal deformities, Hirschsprung’s disease, Ear/Eye anomalies, Cleft 
palate/Cryptorchidism and Kidney dysplasia. 
KAUFMAN-McKUSICK SYNDROME: 
In this syndrome HD associated with Hydrometrocolpos, postaxial 
polydactyly, congenital heart defect. 
Aside from, number of unusual hereditary syndromes has been 
reported in patients with HD, which includes Smith-Lemli-Opitz 
syndrome, Cartilage-hair hypoplasia syndrome Mowat-Wilson syndrome, 
Down syndrome and syndromes with HD and distal limbs anomalies [52]. 
CLINICAL PRESENTATIONS: 
 Hirschsprung’s disease is the disease of the new-born. It is 
suspected if the child doesn’t pass meconium within 48 hours after birth. 
This classical presentation may be absent in 6% to 42% of the patients 
according to Teitelbaum et al. Other symptoms are signs of lower 
intestinal obstruction such as abdominal distension and bilious vomiting. 
Hirschsprung’s disease can also first present itself as enterocolitis and 
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sepsis, mainly in the more extended forms. The neonate with HD is 
usually a full-term baby. The diagnosis of HD in the newborn period is 
made in 90.5% of patients. After the new-born period, the most common 
presentation is constipation, abdominal distension accompanied with 
failure to thrive. But all these are not specific. 
The clinical differentials at this stage include, 
• Obstructive lesions - Colonic atresia or duplication, meconium 
plug syndrome, anorectal anomalies and malrotation etc.. 
• Neurological Lesions - Intestinal neuronal dysplasia (IND), 
hypoganglionosis and similar conditions. 
• Endocrine and metabolic disorders causing obstructive symptoms. 
Hypoganglionosis: 
Isolated hypoganglionosis represents only 5% of intestinal 
neuronal malformations [53]. Only full thickness biopsies are reliable for 
establishing the diagnosis of hypoganglionosis, as analysis of the 
intramural plexus is essential. In this, number of ganglion cells per nerve 
unit in the myenteric plexus is decreased and the interganglionic distance 
is significantly increased [54, 55]. Usually less than 14 ganglion cell per 
centimetre and decreased nuclear diameter of ganglion cells [56]. In 
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addition, it is also characterized by a reduction in the number of LDH-
positive nerve cells in the myenteric plexus and a scarcely developed 
network of parasympathetic nerve fibres in the circular and longitudinal 
muscles with a low AChE activity. 
Intestinal Neuronal dysplasia: 
Intestinal neuronal dysplasia (IND) is a malformation of the ENS 
and is a controversial entity. In most patients, IND is clinically 
indistinguishable from Hirschsprung’s disease at presentation. Some 
investigators have reported that 25–35% of patients with HD have 
associated IND [57]. Two forms are recognised: IND A and IND B. 
 IND type A (Hypoganglionosis) is characterized by the lack or 
immaturity of sympathetic innervation of the myenteric plexus. This 
condition is extremely rare.  
 IND type B (Hyperganglionosis) is a developmental abnormality of 
the submucosal plexus characterized by the presence of “giant ganglia” 
in the submucosa, ectopic ganglion cells in the lamina propria, muscularis 
mucosa and inner circular muscle. Abnormal increase in 
acetylcholinesterase positive nerve fibres with in the lamina propria and 
around submucosal blood vessels are also present [58]. Normally 
innervated colonic mucosa contains 4 ± 2 ganglion cells where as IND 
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type B show 10 ± 2 ganglion cells per ganglia [59]. If 15–20% of the 
submucosal ganglia in the rectal biopsy are giant ganglia, a diagnosis if 
IND type B is appropriate. The nerve cells in the giant ganglia are 
significantly smaller and anisomorphous compared with those in normal 
biopsies. However, the reproducibility of the histological diagnosis 
remains doubtful. 
The histopathological findings in HD are explained in detail below.  
CLASSIFICATION OF HD: 
1. Short segment disease (Classic HD) – the aganglionic segment 
does not extend beyond the upper sigmoid colon. Most common 
form of HD constitute 75% to 80% involves Distal sigmoid colon 
and rectum. 
2. Long segment disease - aganglionosis extends to the splenic flexure 
or transverse colon .The disease extends beyond the splenic 
flexure. It comprises about 15% to 20%. 
3. Total colonic aganglionosis (TCA) – aganglionic segment extends 
from the anal canal to at least the ileocecal valve but does not 
extend more than 50 cm beyond the ileocecal valve. The incidence 
of this form is 5% to 10%. Male to female ratio is equal in TCA. 
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4. Ultra short segment disease - UHD is defined as an aganglionosis 
in the anal canal, proximal to the pectinate line about 3–4 cm in 
length. An absolutely accurate diagnosis of UHD is only possible 
with an enzyme histochemical AChE reaction [60]. 
5. Total intestinal aganglionosis - Total intestinal aganglionosis with 
absence of ganglion cells from duodenum to the rectum is the rare 
form of HD [61]. 
6. Zonal aganglionosis – zonal or segmental (skip) aganglionosis in 
which the absence of ganglion cells is patchy, so the surgical 
correction may fail [62]. 
Depending on the time in which the neural crest cell arrest takes 
place the involved segment varies. If it is inhibited by 8th week of 
gestation then the affected region is the entire colon. Affected segment is 
descending colon along with recto sigmoid if there is arrest by 9th week of 
intra uterine life. Only the recto-sigmoid is affected if there is delay in the 
arrest as late as 10-12th week of intrauterine life. Long segment 
aganglionosis is the result of early arrest. The aganglionosis is continuous 
and uninterrupted until the proximal transitional zone is reached. 
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Figure 2: Extent of HD (stippled area), A: Short segment HD, B: 
Ultrashort segment HD, C: Long segment HD, D: Total colonic 
aganglionosis, E: aganlionosis extends into distal small bowel. (Adapted 
from Stocker& Dehner’s   pediatric pathology, 3rd edition, chapter 14, page no 594). 
INVESTIGATIONS:  
Ano rectal manometry: 
Rectal inhibitory reflex is elicited by distending the rectum and 
monitoring the response of the internal anal sphincter. This test is reliable 
only after 12th perinatal day. Two to sixty ml of air is insufflated to elicit 
this response. Internal sphincter pressure of 5mm Hg for 2-5 seconds is 
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considered to be normal after distention. This recto anal inhibitory reflex 
is absent in HD [63]. 
It has limitation like false negative value in case of probe 
displacement, difficult in case of un-cooperative children and false 
positive results in case of insufficient inflation and air leak. 
Radiological diagnosis: 
Plain X- ray finding that clinch the diagnosis include absence of 
gas shadow in the narrowed rectum and dilated proximal colon. Supine 
and lateral decubitus plain films are performed routinely. The level of 
obstruction may be indicated by the presence of undistended colon or 
rectum. Barium enema confirms diagnosis with cone-shaped or funnel-
like appearance of the transitional zone between the distended proximal 
bowel and the narrowed aganglionic distal segment. 
 It has disadvantages like radiation exposure and when rectal wash 
is given, the dilated portion is decompressed masking the typical picture. 
ROLE OF HISTOPATHOLOGY IN DIAGNOSIS: 
 Although clinical and radiological correlations are essential, the 
“gold standard” diagnostic modality is histopathological examination. 
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Specimen:  
Rectal biopsy whether it may be suction biopsy or full thickness 
biopsy is the most common procedure performed to diagnose HD. 
Sometimes intra operative rectal biopsy is carried out for the analysis of 
enzyme histochemistry using frozen sections. 
Rectal suction (mucosal) biopsy (RSB) remains the favoured 
approach in neonates and young infants, as contemporary biopsy guns 
yield diagnostic specimens (3.5–5 mm in diameter, with at least 2 mm of 
submucosa) with minimal morbidity. The suction device relies on 
vacuum to elevate and excise an adequate tissue. RSB can be done at 
bedside without the need for general anaesthesia or suturing and is less 
traumatic to the patients. Diagnosis of aganglionosis is made in either 
plexus (submucosal or myenteric), since at any level aganglionosis of 
both plexuses is synchronous. Simplicity and absence of complications 
strongly favour RBS as the procedure of choice for the diagnosing HD 
nowadays [64]. 
Full thickness biopsy is preferred for older infants and children 
[65], as RBS is more prone to produce inadequate specimens, probably due 
to over distention of the rectal wall, mucosal edema, or increased fibrous 
tissue, making it difficult for the suction device. It may be open or 
endoscopic guided biopsy which aims to obtain a larger volume of tissue 
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from a well-controlled location. It requires general anaesthesia and may 
be followed by complications like bleeding, perforation, and scarring. 
Also diagnosis of aganglionosis is made in either plexus, since at 
any level aganglionosis of both plexuses is synchronous. So, many 
institutions prefer rectal suction biopsy rather than full thickness/ 
seromuscular biopsy for primary diagnosis of HD. 
Intra operative biopsy for frozen section with AChE enzyme 
study can helps in immediate diagnosis and guides the surgeon on the 
level of transection of the bowel in the same sitting. 
 Apart from initial diagnosis, biopsies may be performed several 
times like, at enterostomy, again during pull through surgery, and 
sometimes again due to persistent constipation. 
Diagnostic accuracy depends on the adequacy of the specimen and 
biopsy site. Biopsy should be taken  2-3 cm proximal to the pectinate line 
(transition between rectal and squamous mucosa).A number of studies 
have demonstrated that the anal canal and the distal 1-2 cm of rectum is 
normally hypoganglionic or aganglionic, and a justifiable concern exists 
that sampling of these areas may lead to a false positive impression of 
aganglionosis[66, 67]. Also, biopsies taken too high may miss very short 
segment HD limited to the distal rectum.  
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According to Aldridge and Campbell study, at least two biopsies 
should be obtained [66]. However, no universal standard exists, and some 
practitioners recommend more extensive sampling. A minimum, a 
diagnostic biopsy should measure approximately 3mm in diameter and 
have at least one-third to half of submucosa. An accepted rule of thumb is 
that in a well oriented biopsy the portion of submucosa sampled should 
be at least as thick as the overlying mucosa. 
Unsatisfactory or inadequate biopsy:  
Biopsies are reported inadequate when, 
1. No or very minimal sub-mucosa is present; 2.Sub-mucosa is 
occupied by a lymphoid follicle; 3.Specimen is decomposed; 4.Specimen 
reveals stratified squamous epithelium (‘low biopsy’ from anal canal). 
When a Resected bowel specimen is received after surgery it is 
processed for H&E examination. The slides are evaluated for presence of 
ganglion cells at the proximal resected margin. The presence of ganglion 
cells in proximal margin ensures the adequacy of resection while its 
absence helps in guiding the surgeon to select the colostomy site. 
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Microscopic features: 
 The characterized finding of HD is aganglionosis in both the 
submucosal and myenteric plexus and presence of hypertrophied nerves 
in the submucosa. So, deep insight about normal bowel morphology and 
ganglion cell, nerve plexus distribution in various layers of intestine is 
necessary. 
 
Figure 3: Diagrammatic representation of cross-section of bowel layers 
and nerve plexus distribution.  
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The intestine is a tubular structure and has four distinct functional 
layers (from lumen to outside) – Mucosa, Submucosa, Muscularis propria 
and Serosa. The mucosa is made up of lining epithelium, lamina propria 
and muscularis mucosa. Muscularis propria has inner circular and outer 
longitudinal muscle layers (Fig 3). 
There are three plexuses in the intrinsic nervous system which 
includes the inner Meissner’s (Submucosal) plexus found only in the 
small and large intestine which lies just beneath the muscularis mucosa. 
The deep submucosal  plexus or Henle’s plexus lies close to the surface 
of the circular muscle layer and the outer Auerbach’s (Myenteric) plexus 
(Figure: 6) running the full length of the gut between the longitudinal and 
circular smooth muscle layers consists of unmyelinated nerve fibres, 
clusters of rounded Schwann cells and large ganglion cells around the 
perimeter of nerve fibres. 
GANGLION CELLS: 
Ganglion cells are contained within “neural units” first described 
by Yunis[68]. They are typically large polygonal cells having amphophilic 
to basophilic cytoplasm which contains Nissl’s granules with eccentric 
nuclei and prominent nucleoli. Normally, one to five ganglion cells are 
seen in clusters at equi-distance for every 1mm of normal rectal mucosa 
[66] (Mean myenteric ganglion cell density in Colon is 7ganglion 
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cell/mm). Their arrangement in clusters and their association with nerves 
facilitates recognition. In neonates and premature infants, the ganglion 
cells are often smaller, without a recognisable nucleoli and cytoplasmic 
Nissl’s granules are also absent, making its identification more difficult 
particularly in the submucosal plexus. 
Additional H&E findings in HD: 
Thickened nerve fibres: 
Absence of ganglion cells in an adequate biopsy is diagnostic of 
HD and the presence of numerous unusually large, prominent submucosal 
and myenteric Schwannian nerve elements are regarded as useful 
supportive feature in making diagnosis. These hypertrophic nerve fibres 
more than 40µm in diameter strongly correlate with abnormal 
innervation/aganglionosis [69]. But these hypertrophic nerve fibres are less 
common in ultrashort segment HD, long segment HD (LHD), TCA and 
also in young infants [70, 71]. 
Histological grading system for HD: 
Teitelbaum et al. proposed in 1989 that the presence of HD implies 
an alteration in the mucins of the large bowel with associated mucin 
retention and crypt dilatation [72]. They proposed a histological grading 
system ranging from normal to gross abnormality using both histological 
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features and the feature of mucin retention which is unique to HD and 
also cystic fibrosis (Table:1). Using this grading system we can identify 
patients with histopathological Hirschsprung’s disease associated 
enterocolitis (HAEC) in the suction rectal biopsies before they became 
symptomatic. HAEC is a serious complication that can occur pre- or post 
resection of the aganglionic bowel and clinically manifest as abdominal 
distension and diarrhea, usually accompanied by fever and often bloody 
stools. Grade III or higher in this grading system predict the development 
of enterocolitis in patients with HD [72]. 
Table 01: Histological grading system for Hirschsprung’s disease 
Grade Histopathological features 
0 No abnormalities 
I Crypt dilatation and mucin retention 
II Cryptitis or two crypt abscesses 
III Multiple crypt abscesses 
IV Fibrinopurulent debris and mucosal ulceration 
V Transluminal necrosis or perforation 
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   Before issuing a definitive report, it is necessary to examine serial 
sections of paraffin embedded tissue to establish the diagnosis of 
aganglionosis. In practice, it is recommended that at least six slides, each 
bearing a ribbon of 6 to 10 serial sections should be evaluated when the 
ganglion cells are absent. 
Limitations of H&E in diagnosis of HD: 
Rectal suction biopsy (RBS) is becoming the procedure of choice 
for obtaining specimens for the initial diagnosis of HD because of its low 
morbidity. Morphologic immaturity of ganglion cells especially in 
neonates and infants, and sparse distribution of ganglion cells in the 
submucosal plexus need careful evaluation of many sections (more than 
50) before a biopsy can be interpreted as negative for ganglion cells. It is 
a time consuming process when routine H&E is used alone [73]. Also, 
immature morphology of ganglion cells in neonates can be confused with 
endothelial cells or neuronal cells leads to false negative diagnosis. 
Sampling error is another major factor in wrong diagnosis. False 
positivity can occur if the site of biopsy is too distal due to physiological 
paucity of ganglion cells. Superficial biopsy without enough submucosa 
can also result in patient being wrongly diagnosed as HD. 
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In order to overcome these limitations, many ancillary techniques 
have been proposed to improve the detection rates, reduce false positivity 
and increase the reproducibility and the ease of diagnosis. 
ANCILLARY TECHNIQUES: 
Nowadays, full thickness specimens are being replaced by suction or 
mucosal rectal biopsies in the diagnosis of HD. Interpretation is more 
difficult in these specimens using H&E alone. Ancillary techniques like 
enzyme histochemistry and IHC staining may encourage more and more 
pathologists and surgeons to prefer suction biopsies instead of the more 
invasive full thickness specimens. 
I. HISTOCHEMICAL STAINING 
Acetylcholinesterase (AChE) enzyme study: 
AChE enzyme study is the most widely accepted histochemical 
stain to diagnosis HD. The principle of the histochemical staining is 
based on the original technique of Karnowsky and Roots [74]. It requires 
examination of fresh, unfixed specimens. The specimens are subjected to 
10-12 µm thick sections for proper highlight of nerve fibres. Normally 
innervated intestinal mucosa does not generally stain for AChE [75]. So, 
the presence of increased density and thickness (coarse) of AChE positive 
cholinergic nerve fibres in the lamina propria between the crypts and 
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muscularis mucosae is regarded as highly specific for the HD diagnosis 
[76]. Demonstration of the AChE-positive nerves in the aganglionic zone 
appears to correspond with the severity of the clinical presentation and 
degree of obstruction in HSCR as well according to Garrett et al [77]. 
While all techniques look at the absence of ganglion cells, this is 
the only ancillary technique where a positive result is diagnostic of HD. 
The main advantage of this technique is its quick diagnosis, rapid 
procedures have been developed to reduce the time to 5-10 minutes [78, 79], 
instead of traditional protocol for AChE staining which requires 
approximately 90 minutes. Hence definitive treatment can be planned in 
the same setting. 
However, the technique is not without limitations and they have been 
addressed in many studies [80, 81].  
- Needs fresh tissue sample, cryostat, interrupting the usual 
workflow of a surgical pathology laboratory. 
- Possible need for extra biopsy for H&E 
- AChE is a unique histochemical stain used only for HD and has 
cost implications in using it. 
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- It requires freshly prepared reagent [82] and is a difficult 
histochemical stain to perform. 
- Results are influenced by improper tissue handling and staining 
quality. 
- False negative results can occur especially in young infants [83] or 
ultra short segment HD and TCA [84, 85]. In TCA, AChE staining 
pattern may appear almost normal due absence of submucosal 
hypertrophic nerves, limiting its application. 
- AChE studies are subjective as they require both qualitative and 
quantitative assessments [86] and studies have also shown more 
disagreements in the interpretation of AChE stain [21]. 
Other histochemical stains: 
 A variety of histochemical stains like Lactate dehydrogenase 
(LDH), Alpha-naphthyl esterase, NADPH-diaphorase which highlights 
the enzyme present in ganglion cells and Toluidine blue and others can 
support the diagnosis of HD. 
 LDH is a complementary enzyme study for HD. However it plays 
a major role in diagnosis of Hypoganglionsis and Intestinal neuronal 
dysplasia. 
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  Due to the absence of ganglion cells in the aganglionic segment of 
HD patients, there is an absence or marked reduction of NADPH 
diaphorase positive nerve fibres in both muscle layers and the muscularis 
mucosae. The typical hypertrophied nerve trunks appear weakly stained 
[87].  
 Toluidine blue is a metachromatic dye, has an affinity for nucleic 
acids, and therefore binds to nuclear material with a high DNA and RNA 
content, and to chromatin or Nissl substance in the cytoplam. It 
selectively stains ganglion cell nucleus blue and cytoplasm light blue 
allowing for easy identification of these cells and can be a very useful 
adjunct to H&E [88]. 
II. IMMUNOHISTOCHEMICAL TECHNIQUES: 
As a means to improve the diagnostic accuracy of HD over H&E 
and to overcome the limitations of AChE staining, other reliable 
diagnostic methods like IHC has been tried to facilitate diagnosis. In 
recent years, the use of several markers have been attempted to aid the 
diagnosis of this disorder, including S-100 protein [89, 90], neuron specific 
enolase (NSE) [90], glial fibrillary acid protein (GFAP) [91, 92], glucose 
transporter 1 (GLUT-1) [93], microtubule associated protein 5 (MAP-5) 
[12], CD56, Synaptophysin, Chromogranin A, Cathepsin D, Vimentin, 
Bcl2, and others [94]. IHC staining has the advantage of using sections 
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from paraffin embedded biopsies, thus eliminating the need to obtain 
extra biopsies. Also this technique is available in most pathology 
laboratories. 
Synaptophysin and Chromogranin A show lower sensitivity, 
specificity and reactivity to ganglion cells, making them less reliable and 
less useful diagnostic markers for Hirschsprung’s disease and allied 
disorders, although synaptophysin shows strong staining of myenteric 
plexuses which makes it a good diagnostic marker for hypertrophic or 
hypotrophic changes of extrinsic nerve fibres [95].  
S100 immunostain is a nerve sheath marker used to highlight the 
nerve hypertrophy. Besides S100 can be utilized as an indirect marker of 
the presence ganglion cells which identifies the ganglion cells as 
prominent negatively stained cells and surrounded positive Schwann cells 
and nerve fibres. They can highlight the presence of hypertrophic nerve 
fibres and presence of ganglion cells bodies by their lack of staining. 
NSE IHC stains the ganglia intensely, helping in the recognition of 
small immature ganglion cells. 
Several other immunohistochemical markers have been tested, but most 
of them have limitations for use in daily practice [80]. 
 
38 
 
CALRETININ:
 
 Calretinin is a 29 kDa calbindin and a member of EF hand protein. 
It is a Vitamin D dependent calcium binding protein, palys a role in 
various cellular functions including message targeting, physiological 
buffering of excess intracellular calcium ions and gives protection against 
calcium ion overload [96]. Calretinin is abundantly expressed in neurons 
including retina (hence the name) [97], cortical inter neurons. Calretinin 
has been shown to have a broad tissue distribution like mesothelium, 
Sertoli & Leydig cells of testis and mast cells etc which also includes 
strong expression in neural elements [98]. Nerve cell bodies (ganglion 
cells) and nerve fibres in both submucosa and myenteric ganglia in the 
human gastrointestinal tract are immunopositive for Calretinin [99]. Loss 
of Calretinin immunoreactivity in ganglion cell and nerves has been 
documented by many authors, to be characteristic of HD. 
McConalgue et al in 1994 was the first to show in the large 
intestine of guinea pigs that Calretinin immunoreactivity highlights 
different neuronal populations[100]. Since then a number of comparative 
studies have been published on the expression of calretinin in HD and its 
utility as a marker for assisting in the diagnosis of HD. Barshack et al 
utilized this Calretinin reactivity to diagnose HD in the year of 2004. 
Calretinin immunorectivity was studied in ten large bowel full thickness 
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specimens (a total 54 paraffin wax blocks) from patients with classic 
rectosigmoid HD. Calretinin was not expressed in aganglionic segments 
of HD and associated nerve fibres, whereas both ganglion cells and nerve 
fibres were immunopositive in ganglionic HD segments and in normal 
colon. The transitional zone showed a broad spectrum of 
histomorphological and immunohistochemical patterns of calretinin 
expression [101]. 
Kapur et al compared calretinin versus acetylcholinesterase 
(AChE) in normal and HD patients concluding that calretinin is superior 
to AChE as an adjunct diagnostic method for HD. Multiple observers 
independently reviewed calretinin IHC and AChE sections of suction 
biopsies from 14 HD and 17 controls. There were 2 misdiagnoses and 
more disagreements in the interpretation of AChE-stained sections, but 
calretinin IHC showed no misdiagnoses or discrepancies [81]. They 
concluded that calretinin IHC to be a better alternative to AChE as an 
adjunct in  diagnostic method for evaluating suction rectal biopsies for 
HD [81]. One major problem  reported in cases of AChE interpretation was 
high interobserver disagreements. Calretinin IHC substantially reduces 
this problem and appears to be a superior alternative to AChE. Also they 
observed  punctate axonal immune staining of hypertrophied nerve fibres 
in few HD cases in their study.
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Similar observation was published in 2009 by Guinard-Samuel et 
al. They evaluated the calretinin immunostaining as a primary diagnostic 
tool on a large series of suction rectal biopsies [102] .They retrieved 131 
biopsies carried out for suspicion of HD in children and infants to 
compare the accuracy of calretinin immunohistochemistry with the 
standard method (histology and acetylcholinesterase staining). In their 
study, calretinin immunohistochemistry enabled the diagnosis of all HD 
diagnosed by the standard technique, except for one patient who had a 
weak positive immunostaining in some nerve fibers (false negative case). 
It is important to note that 12 additional cases initially considered as 
suspicious for HD using the standard technique were accurately 
diagnosed by calretinin immunohistochemistry. The authors also noted 
faint positive staining of some nerve fibers with Calretinin IHC but with 
no other staining (ie, muscularis mucosae, lamina propria or nuclear 
staining) in authentic HD. To avoid this potential and exceptional pitfall, 
authors suggested, Calretinin should be used in combination with 
standard histology and that it might be more accurate than 
acetylcholinesterase in detecting aganglionosis [102]. 
 Hiradfar M et al in 2012, in their study evaluated 80 paraffin 
blocks, previously fixed in 10% buffered formalin. Those comprised 30 
blocks from the aganglionic zone, 30 from the ganglionic zone and 20 
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blocks from control group. Calretinin immunoreactivity and pattern of 
staining for ganglion cells (nuclear and cytoplasmic) and also nerve fibres 
in different layers of bowel (lamina propria, muscularis mucosa, 
submucosa and muscularis propria) were evaluated in IHC stained slides.  
Calretinin IHC showed a sensitivity and specificity of 93.3% and 100% 
respectively for diagnosing HD in full thickness biopsies of intestinal 
wall. The positive predictive value and negative predictive value were 
100% and 93.8%. There was no false- positive or false negative results 
based on calretinin immunostaining in submucosa. They concluded it can 
be used on suction rectal biopsies as a reliable adjunctive method to 
diagnose HD [103].  
An another study  evaluating calretinin staining pattern in both 
ganglionic and aganglionic segment showed that Calretinin IHC stain 
highlighted the ganglion cells, submucosal and subserosal nerve trunks in 
normal rectum. Also, it is expressed in a linear, granular pattern, in the 
nerve fibrils of the superficial submucosa, muscularis mucosae and 
lamina propria. However, Calretinin immunohistochemical stain was neg-
ative in the aganglionic segments of bowel examined.  Nerve fibrils in 
lamina propria, muscularis mucosae or superficial submucosa stained 
negative for Calretinin. Occasional cells, possible mast cells, expressed 
calretinin in the submucosa both in ganglionic and aganglionic segments, 
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which can be used as an internal control for assessing quality of staining.  
Unexpectedly, two of 13 HD biopsy specimens which showed no 
ganglion cells and no Calretinin immunoreactivity in any of the 
compartments, showed a faint, granular, axonal reactivity in the 
submucosal hypertrophied nerve trunks [104]. These findings were also 
observed in the nine pull through specimens in which calretinin was 
performed on the sections showing the transition from affected-to-unaf-
fected bowel. No explanation could be provided for this pattern by the 
authors. Guinard-Samuel et al. believed that this positive staining of some 
nerve fibers could indicate the beginning of transitional zone [102]. 
Kannaiyan L et al. [104] in their Indian based study of sixty cases 
including 34 initial full thickness colon biopsy and 26 resected 
specimens, found that calretinin correlated with H& E examination in 
both rectal biopsies and the resected bowel specimens. In the rectal 
biopsy specimens, calretinin also aided in the diagnosis of 15 patients 
with ambiguous findings and they concluded that Calretinin was 
extremely useful in solving the suspicious and indeterminate cases of HD. 
It can serve as a valuable costeffective diagnostic aid in the centers 
where acetylcholinesterase enzyme histochemistry is not available [105]. 
Mukhopadhyay B et al selected one hundred and five blocks for 
calretinin IHC. All representative areas including lamina propria, 
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submucosa, and muscularis mucosae were examined for detection of 
calretinin positivity by two pathologists blindly. Satisfactory concordance 
was obtained between H&E reports and calretinin study. Overall 
sensitivity, specificity, positive, and negative predictive value were 
100%, 92.73%, 92.45%, and 100%, respectively [106]. 
 Rakhshani N et al studied a total ninety four cases and compared 
concordance between H&E diagnosis and Calretinin IHC diagnosis. 
Results showed that disagreement between calretinin IHC and H&E 
staining in identification of ganglion cells occurred in 3 cases, whereas 
disagreement between calretinin IHC and H&E staining in identification 
of intrinsic nerve fibres occurred in 4 cases. Comparing the values of 
specificity and accuracy between calretinin and standard histology 
(H&E), by the Fisher exact test, calretinin presented significantly (P 
value <0.0001) higher specificity and accuracy values than H&E staining. 
The measure of agreement by Kappa test showed there were high 
agreement in IHC and H&E staining of Ganglion Cells and it was 
significant rather than with intrinsic nerve fibres (P value <0.0001) [107]. 
The immunoreactivity of three IHC markers, viz., Calretinin, 
synaptophysin and chromogranain were compared and recored as 1+, 2+ 
or 3+ based in intensity of immunoreactivity. Calretinin showed the 
highest reactivity ( mean score of  2.47) for ganglion cells when 
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compared to other neuronal markers like synaptophysin (0.58) and 
chromogranin A (0.63) [95]. 
Another additional benefit of calretinin immunostaining is the 
presence of positive control in the sections of the submucosa, i.e. some 
non neuronal cells such as histiocytes and mast cells showed cytoplasmic 
and nuclear immunoreactivity that can be considered as internal positive 
control. 
Calretinin immunohistochemistry is done on paraffin sections and 
its interpretation which is based on negative or positive results is much 
easier [81, 102]. 
Limitations of Calretinin: 
• Calretinin showed only a moderate reactivity for nerve plexus when 
compared to other neuronal markers like synaptophysin and 
chromogranin A. [95] 
• Several previous reports also have noted the possibility of false 
negative results in calretinin IHC due to immunostaining in some non 
neuronal cells [101,102]. 
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• Unlike AChE staining which can provide diagnosis intraoperatively, 
Calretinin IHC can be done only in processed tissues. Repeat biopsy 
may be required in case of inadequate sample. 
• Because of the phenotypically heterogeneous nature of HD [81], the 
utility and efficacy of calretinin immunohistochemistry, especially in 
ultrashort segment HD or transitional zone assessments, remains 
unexplored. So, calretinin immunohistochemistry should always be 
used in addition to H&E sections while evaluating for HD thus adding 
to the cost. 
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MATERIALS AND METHODS 
STUDY DESIGN 
 The present study is a retroprospective study. Retrospective study 
period is August 2016- November 2016 and Prospective study period is 
December 2016- March 2018. A total sample of 30 cases of suspected 
Hirschprung’s disease was analysed. 
Ethical clearance for the study was obtained from the Ethics Committee 
of Coimbatore Medical College, Coimbatore. 
STUDY SETTING 
 The study is undertaken in the Department of Pathology, 
Coimbatore medical College and Hospital, Coimbatore. 
STUDY PERIOD 
 August 2016 to March 2018 
SELECTION CRITERIA 
1.  Inclusion criteria 
 Age: Day1 to 15 years 
 Gender: Both sexes 
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 All clinically suspected cases of Hirschsprung’s disease who 
underwent rectal biopsy or bowel resection. 
2. Exclusion criteria 
 Ill fixed specimen or specimen not sent in formalin. 
 Biopsy specimen which contains the epithelium of the anal canal or 
skeletal muscle. 
SPECIMEN RECEPTION AND PROCESSING: 
 The study was done in 30 biopsy or resected bowel specimens 
of clinically suspected Hirschprung’s disease, received from 
Department of Pediatric Surgery, Coimbatore Medical College and 
Hospital, Coimbatore. 
Processing of fresh specimens: 
  The specimens were received in 10% formalin for routine 
histopathological examination with a request form containing the 
necessary history, investigation details and information about the 
specimen. The specimens were fixed in formalin for 8-12 hours. In case 
of rectal biopsy specimen, the whole specimen was embedded. Resected 
bowel specimens were evaluated grossly and representative samples were 
taken each from distal spastic segment, transitional zone, and proximal 
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ganglionic region. Sampling of proximal margin is most important and 
we did circumferential sampling of proximal end. 
Sampled specimens were processed in an automated tissue 
processor (LEICA TP1020) for 16 hours and then embedded in paraffin 
wax. Blocks were sectioned using microtome for H&E and Calretinin 
IHC as explained below. 
Collection of specimens for retrospective data: 
All cases of suspected HD who underwent rectal biopsy or 
bowel resection between August 2016 and November 2016 were 
retrieved from pathology records. The blocks and H&E slides of 
these patients were collected and processed for further analysis. 
Blocks were cut 4µm thick using microtome for Calretinin IHC 
staining and for H&E if required. 
Hematoxylin & Eosin staining was done in our laboratory 
using Erhlich’s hematoxylin for 10-15 minutes. 
Calretinin IHC staining process: 
Sections cut from microtome were collected on ‘coated’ 
slides, prepared using 2gms Gelatin, 1gm chromalum, pinch of thymol 
crystal added in 200ml of distilled water and heated at 300˚C for 1min. 
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IHC staining was performed on paraffin embedded tissues, using the 
following  
BUFFERS AND CONSTITUENTS 
 TRIS EDTA BUFFER: pH – 9 
TRIS buffer salt – 6.05 gms 
Disodium EDTA – 0.74 gms 
Distilled water – 1000 ml 
 TRIS BUFFER SALINE: pH – 7.6 to 8 
TRIS buffer salt – 0.605 gms 
Sodium chloride – 8 gms 
Distilled water – 1000 ml 
1N Hydrochloric acid – 3.5 to 4ml 
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Figure 4: Schematic representation of IHC procedure (Indirect method) 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4µm sections were taken on the coated slides. 
2. Slides were incubated overnight in incubator at 60˚C 
3. Tissue sections deparaffinised in Xylene for ten minutes – 3 
changes 
3. Washed using absolute alcohol for five minutes – 2 changes 
4. Washed with tap water for five minutes  
5. Rinsed in distilled water for two minutes 
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6. Antigen retrieval – done by placing the slides in a microwave with 
Tris EDTA buffer for 20 minutes (ten minutes each at 450˚C and 
800˚C). 
7. Cooled it in room temperature and then rinsed in distilled water 
8. Peroxide block applied on sections for 10 minutes  
9. Washing was done in TBS buffer for five minutes – two changes 
10.  Drained the slide and added Primary Antibody- Calretinin (Rabbit 
monoclonal Calretinin antibody, Clone EP1798, Bio SB )which 
was followed by incubation at room temperature in a moisture 
chamber for one hour 
11. TBS buffer wash for five minutes – two changes 
12. Slides covered with Secondary antibody – Bio SB - Mouse / 
Rabbit PolyDetector/ HRP label for 30 minutes. 
13. Washed in TBS buffer for five minutes – 2 changes 
14.   DAB chromogen was diluted with Bio SB buffer substrate and 
applied for five to eight minutes. 
15.  Rinsed in distilled water 
16.  Counterstaining was done with Harris hematoxylin for 1 minute 
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17.  Blueing for five to ten minutes 
18. Slides air dried, cleared in Xylene and mounted in DPX. 
All biopsies received with clinical diagnosis of suspected HD were 
included. 22 full thickness biopsies and 8 resected specimens were 
received during the study period. One ganglionic segment and one 
aganglionic segment of the 22 biopsies (total 44 paraffin blocks) were 
processed for each case. In the 8 resected specimens, representative 
tissues taken from dilated ganglionic, spastic aganglionic and transition 
zone (total 24 paraffin blocks) were processed. On the whole sixty eight 
paraffin blocks were studied. 
Hematoxylin & Eosin interpretation: 
Slides from all 68 paraffin blocks were stained with H&E and 
examined carefully under the light microscope, independently by two 
pathologists, one who is experienced in diagnosing HD (observer 2) and 
another who has limited experience with HD reporting (observer 1). 
Presence or absence of ganglion cells and hypertrophied nerve bundles 
were recorded separately for submucosa and muscularis propria as binary 
variables in ganglionic segment. Similar findings were recorded for 
aganglionic segments as well. If the results were doubtful or suspicious it 
was recorded as equivocal. Positive interpretation of Non-Hirschsprung’s 
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disease (NHD) was based on the identification of at least one ganglion 
cell in a representative serial sections in either submucosal or myenteric 
plexus. The absence of ganglion cells with or without hypertrophic nerve 
fibre in submucosa and muscularis propria was considered as HD. 
Calretinin IHC interpretation: 
All corresponding sections of 68 blocks were stained with 
Calretinin IHC by above mentioned procedure and evaluated for 
immunoreactivity by the same two observers blinded both from each 
other and from the initial H&E diagnosis. Calretinin immunoreactivity 
and pattern of staining for ganglion cells and nerve fibres in different 
layers of bowel including lamina propria, muscularis mucosa, submucosa 
and muscularis propria were evaluated for both ganglionic and 
aganglionic segments of the IHC stained slides independently by two 
pathologists. Results were recorded separately for all four layers. 
Calretinin was considered as positive if any of the specific findings 
below were present:  
1) Intense, granular and linear staining of nerve fibres in the lamina 
propria, muscularis mucosa, submucosa and muscularis propria  
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2) Diffuse strong cytoplasmic and nuclear staining of ganglion 
cells in the submucosal and/or in the myenteric plexus, and the supporting 
Schwann cells and nerve cells (excluding Mast cell immunopositivity). 
Nonspecific cytoplasmic immunoreactivity was present in sparse 
ovoid cells (probably mast cells) in the submucosa of all biopsies and was 
considered as internal positive control. Absence of neural calretinin 
immunoreactivity in both submucosal or myenteric plexus in aganglionic 
biopsies was considered diagnostic of HD. However, large nerves in the 
submucosa which showed axonal immunoreactivity, if present, were 
recorded separately. 
The intensity and pattern of ganglion cells and nerve fibre staining 
were evaluated semi-quantitatively by light microscopy both in 
submucosal and myenteric plexuses. 
IHC reactivity in ganglion cells was evaluated as follows:  
0 – No staining or impossible to visualise ganglion cell,  
1 – Mild staining,  
2 – Moderate staining,  
3 – Strong staining.  
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In ganglion cells, the staining was evaluated both in nucleus and in 
cytoplasm. Reactivity for staining of neural plexuses was evaluated by an 
analogous scale [95]. 
Statistical Analysis 
Data analysis was done by SPSS for Windows. Descriptive data 
were shown as mean ± standard deviation or number of cases and 
percentages. The data of observer 2 was used to assess diagnostic 
performance of Calretinin over H&E (e.g. sensitivity, specificity, positive 
and negative predictive values, and accuracy). We applied Cohen’s k 
coefficient [108] to assess the agreement between the analysis carried out 
by observer 1 and 2 for both H&E and Calretinin immunohistochemistry. 
A p value less than 0.05 was considered statistically significant. 
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OBSERVATIONS AND RESULTS 
Table 02: Age distribution of study population 
Age Frequency Percent (%) 
<1month 15 50% 
1month – Up to 1 Year 11 36.6% 
> 1 Year 4 13.4% 
Total 30 100 
 
 
Most of the patients (50%) presented at less than 1 month of age. Only 
13.4% patients were more than 1 years of age. 
50%
37%
13%
Chart 1: Age distribution
<1month 1month – Up to 1 Year > 1 Year
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Table 03: Gender distribution of study population 
Gender Frequency Percent (%) 
Male 22 73.3% 
Female 8 26.7% 
Total 30 100% 
 
 
73.3% of the patients presented with clinical diagnosis of HD were males.  
Male: female ratio was 2.75:1. 
73%
27%
Chart 2: Gender
Male Female
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Table 04: Clinical Extent  of  involvement  
Extent of HD Frequency Percent (%) 
SHD 26 86.7 
LHD 3 10.0 
TCA 1 3.3 
Total 30 100 
 
 
Most common form of HD was classic Short segment HD i.e. in 86.7% of 
cases the disease limited to recto sigmoid portion bowel. Total colonic 
aganglionosis was seen in one patient (3.3%). 
87%
10%
3%
Chart 3: Extent of bowel involvement
SHD LHD TCA
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Table 05: Types of specimen 
Specimen Frequency Percent (%) 
Full thickness biopsy 22 73.3 
Resection 8 26.7 
Total 30 100.0 
 
 
Most common type of specimen received in our lab for diagnosing HD 
was full thickness rectal/colon biopsy (73.3%).  Eight patients (26.7%) 
underwent upfront resection. 
73%
27%
Chart 4: Type of specimen
Full thickness rectal biopsy Resection
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Table 06: Positive percentage of ganglion cells based on H&E for 
observer 2 
Bowel layers 
Aganglionic segment Ganglionic segment 
Ganglion 
cells 
N (%) 
Hypertrophic 
nerve fibres 
N (%) 
Ganglion 
cells 
N (%) 
Hypertrophic 
nerve fibres 
N (%) 
Submucosa 4 (13.3%) 19 (63.3%) 26 (89.6%) 
$ 3 (10.3%) $ 
Muscularis 
propria 
5 (18.5%)* 19 (70.3%)* 24 (85.7%) # 3 (7.1%) # 
 
*n=27, $ n=29, # n=28 – The differences in number of samples is due to 
the unavailability of that particular layer in the sample. N=30 in all 
others. 
Submucosa and Muscularis propria showed ganglion cells in 4 and 5 
cases respectively. The presence of ganglion in 5 cases resulted in 
diagnosis of Non-HD. Hypertrophic nerve fibres were seen in around 65-
70% of cases in the study population.  
In clinical ganglionic segment, ganglion cells could not be identified in 
around 13% of cases resulting in sensitivity of 87% for H&E in 
identifying ganglion cells. 
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When five patients with ganglion cells (patients confirmed with NHD) 
were excluded, 19 of 25 (76%) patients and 19 of 22 (as muscularis 
propria was absent in three samples) (86.4%) patients showed 
hypertrophic nerve bundles in submucosa and muscularis propria 
respectively.  
Table 6A: Sensitivity, Specificity and PPV for Nerve bundle hypertrophy 
in diagnosis of HD. 
 HD diagnosed by absence of ganglion 
cells 
Total 
Hypertrophic 
nerve 
bundles 
 Positive Negative  
Positive 19 0 19 
Negative 3 5 8 
Total  22 5 27 
 
Hypertrophic nerve bundles were absent in 3 of 5 patients diagnosed as 
HD by H&E in both layers.  The table for sensitivity, specificity and PPV 
calculation for nerve bundle hypertrophy in diagnosing HD is shown 
above. The sensitivity, specificity and PPV were 86.4%, 100% and 100% 
respectively. 
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Table 07: Hypertrophic nerve fibres in aganglionic segment comparison 
between Short segment HD vs Long segment HD based on H&E for 
observer 2 
Bowel layers 
Short segment n=26 
N (%) 
Long segment n=4 
N (%) 
Submucosa 18 (69.2%) 2 (50%) 
Muscularis propria 17 (73.9%)* 2 (50%) 
*number of samples was 23 (n= 23) as Muscularis propria was not 
included in the biopsy of three patients. 
Hypertrophic nerve fibres were seen in 50% of patients (2/4) with long 
segment involvement and in around 70% of patients with suspected short 
segment involvement. However, when 5 cases of NHD were excluded, 
submucosa and muscularis propria showed nerve hypertrophy in 17 of 21 
and 16 of 18 cases respectively. In short, Hypertrophic nerve bundles 
were present in 84.6% of confirmed short segment HD diagnosed by 
H&E. 
 
63 
 
Table 08: Calretinin IHC expression in both aganglionic and ganglionic 
segments for observer 2 
Bowel layers 
Aganglionic segment Ganglionic segment 
Ganglion 
cells 
Intrinsic 
nerve fibres 
Ganglion 
cells 
Intrinsic 
nerve fibres 
Lamina 
Propria 
NA 5(17.2%) $ NA 24(82.8%) $ 
Muscularis 
mucosa 
NA 4 (13.8%) $ NA 26(89.7%) $ 
Submucosa 5 (16.7%) 8 (26.7%) 26(89.7%) 
$ 26(89.7%) $ 
Muscularis 
propria 
5(18.5%)* 8 (29.6%)* 24(85.7%) # 24(82.8%) # 
*n=27, $ n=29, # n=28 - The differences in number of samples is due to 
the unavailability of that particular layer in the sample. N=30 in all 
others. 
Calretinin expression was seen in 5 cases resulting in diagnosis of NHD 
similar to H&E (Table 6). Of 25 cases diagnosed as HD by ganglion cell 
negativity with IHC, three cases (12% cases) showed immunoreactivity in 
nerve fibres. All five cases with Calretinin immunoreactivity in ganglion 
cells showed immunoreactivity in nerve fibres as well. When nerve fibre 
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immunoreactivity was taken as the criteria for diagnosis, this method had 
a sensitivity and specificity 88% and 100% respectively. 
In clinical ganglionic segment, ganglion cells could not be identified in 
around 13% of cases resulting in sensitivity of 87% for H&E in 
identifying ganglion cells. 
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Table 09: Ganglion cell inference between H&E and Calretinin IHC for 
Observer-1 in aganglionic segment. 
Ganglion cells in 
aganglionic 
segment 
Submucosa Muscularis propria 
H&E Calretinin H&E* Calretinin* 
Positive 5 (16.7%) 5 (16.7%) 5 (18.5%) 5 (18.5%) 
Negative 18 (60%) 25 (83.3%) 16 (59.2%) 22 (81.5%) 
Equivocal 7 (23.3%) 0 6 (22.2%) 0 
*n=27- The differences in number of samples is due to the unavailability 
of that particular layer in the sample. N=30 in all others. 
 
H&E Calretinin H&E* Calretinin*
Submucosa Muscularis propria
5 5 5 5
18
25
16
22
7
0
6
0
Chart 5: Ganglion cells inference between 
H&E and IHC (Observer 1)
Positive Negative Equivocal
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Observer 1, with limited experience, recorded equivocal findings (i.e. 
suspicious of ganglion cells) in around 23% using H&E. However, 
Calretinin IHC could provide a definite answer to this suspicion in all the 
cases. There was no equivocal reading in any of the samples using 
Calretinin IHC. The sensitivity and positive predictive value (PPV) of 
H&E are both 100%. 
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Table 10: Ganglion cell inference between H&E and Calretinin IHC for 
Observer-2 in aganglionic segment. 
Ganglion 
cells in 
aganglionic 
segment 
Submucosa Muscularis propria 
H&E Calretinin H&E* Calretinin* 
Positive 4 (13.3%) 5 (16.7%) 5 (18.5%) 5 (18.5%) 
Negative 23 (76.7%) 25 (83.3%) 22 (81.5%) 22 (81.5%) 
Equivocal 3 (10%) 0 0 0 
*n=27- The differences in number of samples is due to the unavailability 
of that particular layer in the sample. N=30 in all others. 
 
H&E Calretinin H&E* Calretinin*
Submucosa Muscularis propria
4
5 5 5
23
25
22 22
3
0 0 0
Chart 6: Ganglion cells inference between 
H&E and IHC (Observer 2)
Positive Negative Equivocal
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In submucosal layer, by H&E, four samples showed ganglion cells in the 
aganglionic segment and three patients were recorded as suspicious for 
the presence of ganglion. Subsequently, Calretinin IHC showed positivity 
for ganglion cells in one additional patient recorded as negative by H&E. 
All the suspicious cases by H&E stained negative with IHC. There was 
no discrepancy in the detection of ganglion cells in muscularis propria. 
There was no equivocal reading with IHC in both observers. 
The sensitivity and PPV for H&E in our study are 90% and 100% 
respectively. 
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Table 11: Inter observer variation in detecting ganglion cell in the 
aganglionic segment based on H&E. 
Aganglionic 
segment 
Observer 1 Observer 2 
Submucosa 
Muscularis 
propria* 
Submucosa 
Muscularis 
propria* 
Positive 5 (16.7%) 5 (18.5%) 4 (13.3%) 5 (18.5%) 
Negative 18 (60%) 16 (59.2%) 23 (76.7%) 22 (81.5%) 
Equivocal 7 (23.3%) 6 (22.2%) 3 (10%) 0 
*n=27- The differences in number of samples is due to the unavailability 
of that particular layer in the sample. N=30 in all others. 
 
obs1 Obs2 obs1 Obs2
Submucosa Muscularis propria
5 5
4
5
18
16
23
22
7
6
3
0
Chart 7: Ganglion cells inference using H&E
Positive Negative Equivocal
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The positive identification of ganglion did not differ significantly 
between the two observers (10 vs 9 cases) using H&E. However, the 
number of equivocal identifications of ganglion was higher in Observer 1 
(21.6%) compared to observer 2 (5%). 
Concordance of independent observational data by the two observers is 
shown below: 
Table 11 A: Concordance-Discordance table in detecting ganglion cell in 
aganglionic segment based on H&E between two observers. 
 Observer 1 Total 
Observer 2 
 Positive Negative Equivocal  
Positive 7 2 1 10 
Negative 0 39 1 40 
Equivocal 2 4 1 7 
Total  9 45 3 57 
 
There were 57 observations for each observer for detection of ganglion 
cells- 30 in submucosa and 27 in muscularis propria. Both observers were 
blinded from each other and the data was analysed for inter observer 
concordance. The kappa value was interpreted as follows: 
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• Poor agreement = Less than 0.20 
• Fair agreement = 0.20 to 0.40 
• Moderate agreement = 0.40 to 0.60 
• Good agreement = 0.60 to 0.80 
• Very good agreement = 0.80 to 1.00 
In our data, there were 47 agreements and Cohen’s kappa co-efficient was 
0.574 (95% CI 0.36- 0.78). The agreement was moderate. 
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Table 12: Inter observer inference for ganglion cell in the aganglionic 
segment based on Calretinin IHC. 
Aganglionic 
segment 
Observer 1 Observer 2 
Submucosa 
Muscularis 
propria* 
Submucosa 
Muscularis 
propria* 
Positive 5 (16.7%) 5 (18.5%) 5 (16.7%) 5 (18.5%) 
Negative 25 (83.3%) 22 (81.5%) 25 (83.3%) 22 (81.5%) 
Equivocal 0 0 0 0 
*n=27- The differences in number of samples is due to the unavailability 
of that particular layer in the sample. N=30 in all others. 
 
There was no discordance in the indentification of ganglion cells between 
both observers with agreement in all 57 observations resulting in Cohen’s 
kappa of 1.00.
obs1 obs 2 obs1 obs2
Submucosa Muscularis propria
5 5 5 5
25
22
25
22
0 0 0 0
Chart 8: Ganglion cells inference using IHC
Positive Negative Equivocal
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Based on their observations, both observers were required to provide the 
final diagnosis independently. The diagnosis frequency is as below: 
Table 13: Frequency of HD and Non HD based on H&E and Calretinin 
IHC between two observers. 
Number of 
cases 
Initial diagnosis (H&E) 
IHC diagnosis 
(Calretinin) 
Observer 1 Observer 2 Observer 1 Observer 2 
HD 21 (70%) 24(80%) 25 (83.3%) 25 (83.3%) 
NHD 5 (16.7%) 5 (16.7%) 5 (16.7%) 5 (16.7%) 
Suspicious 4 (13.3%) 1 (3.3%) 0 0 
 
 
Obs 1 Obs 2 Obs 1 Obs 2
H&E Calretinin
21
24
25 25
5 5 5 5
4
1
0 0
Chart 9: Diagnosis based on H&E and 
IHC between observers
HD NHD Suspicious
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Of the 30 samples received, 70-80% cases were diagnosed as HD by 
H&E, while 83.3% cases could be diagnosed using Calretinin IHC. This 
shows that around 13.3 % additional cases could be   identified using 
Calretinin over H&E, improving the diagnostic yield. By H&E there were 
4 doubtful diagnosis of HD which could be confirmed using Calretinin 
IHC thus improving the accuracy. 
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Table 14: Calretinin Immunoreactivity Index for ganglion cells in the 
ganglionic segment. 
Calretinin Reactivity 
Index in Ganglionic 
segment 
Numbers 
N=26 (%) * 
2+ 7 (27%) 
3+ 19 (73%) 
*In four cases, samples from clinical ganglionic segment showed no 
ganglion cells; hence excluded from calculation of Calretinin 
Immunoreactivity Index. 
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Figure 5: H&E Section shows  normal layers of the  rectal biopsy (40X) 
Figure 6: Calretinin IHC section shows pattern of staining in the normal 
bowel mucosa and to show Meissner’s plexus, Henle’s plexus and 
Auerbach’s plexus (Black, Pink, Blue arrows respectively) (40X). 
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Figure 7: H&E section shows submucosal – Meissner’s Plexus (arrow) (400X) 
 
Figure 8: Calretinin IHC section shows immunoreactivity in the submucosal 
plexus (400X). 
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Figure 9: H&E section shows location of Auerbach’s plexus between circular 
and longitudinal muscle layer (arrow) (100X) 
 
Figure 10: Calretinin IHC section shows immunoreactivity of myenteric 
ganglia which located at equi-distance for every 1mm of normal rectal mucosa 
(arrowhead) (100X). 
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Figure 11: H&E section shows Ganglion cells (neuronal cell bodies) 
characterized by a large polygonal cells with abundant pink cytoplasm and an 
eccentric nucleus, prominent nucleoli (arrowhead); spindled neural projections 
and Schwann cells(arrow) are also intermixed (400X) 
 
Figure 12: Calretinin IHC section shows strong reactivity to ganglion cells and 
moderate reactivity to nerve plexus (400X). 
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Figure 13: Calretinin IHC section shows lamina propria and muscularis 
mucosa of rectal biopsy with immunopositive thin, linear, granular nerve 
fibrils, in a non-HD case (400X). 
 
Figure 14: Calretinin IHC section shows diffuse strong (3+) cytoplasmic and 
nuclear staining in the submucosal ganglion cells (400X). 
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Figure 15: H&E section shows lack of ganglia in the submucosal plexuses in a 
case HD (100X). 
Figure 16: Calretinin IHC section shows total absence of staining either in the 
submucosa, muscularis mucosa or lamina propria except for mast cells (40X). 
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Figure 17: Calretinin IHC section shows some background staining in the HD 
case, non-neuronal sparse ovoid cells (arrowhead) probable mast cells (400X). 
Figure 18: H&E section shows hypertrophic nerve bundles in the submucosa 
of a HD case (arrow) (100X). 
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Figure 19: H&E section from a HD case shows Hypertrophic myenteric nerve 
plexuses (arrows) lacking ganglion cells (100X). 
Figure 20: Calretinin IHC section from the HD case shows submucosal 
hypertrophic nerve trunk with no immunoreactivity for ganglion cells and 
nerve fibre (400X). 
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Figure 21: A&B Calretinin IHC sections from the aganglionic segment of a 
HD case shows faint, punctate (rather than confluent) immunoreactivity in a 
large calibre myenteric nerve trunk (400X). 
B 
A 
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DISCUSSION 
Our study was done on specimens of 30 suspected cases of 
Hirschsprung’s disease. Patient age ranged from 2 days to 10 years. The 
median age of presentation was 36 days (Inter quartile range between 6 
days and 1year). Of the 30 cases fifteen patients (50%) presented at less 
than 1 month of age, eleven (36.6%) patients between 1 month and 1 year 
of age and four (13.4%) patients after the age of 1year. Kannaiyan L et al 
[105] in their study had twenty three patients (63.8%) at less than 1 month 
of age. Seven (19.5%) patients presented between 1 month and 1 year of 
age. Six (16.7%) patients presented after the age of 1. 
There were 22 boys and 8 girls; Male to Female ratio was 2.75: 1, 
which is similar to Hiradfar M et al [103] and slightly lesser than the 
literature reported ratio of 4:1 [8, 10] possibly because of the lesser number 
of patients. Of these patients 26 (86.7 %) were classic form of HD, 3 (10 
%) long segment form and 1 (3.3 %) total colonic aganglionosis (TCA) 
which is similar to the study of Hiradfar M et al , where evaluated the 30 
HD cases, there were 24 SHD cases (80%), 9 LHD cases (16.7%) and 1 
TCA case (3.3%) [103]. The incidence (10%) of TCA is lower than that 
reported the Indian study by Kannaiyan L et al [105] which is again could 
be due to lesser number of patients. 
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Tissue samples of 30 cases were processed and evaluated for 
ganglion cells and nerve hypertrophy in all the four layers of bowel. 
However, some layers in full thickness biopsy specimens were not 
available for evaluation. The unavailable layers were excluded when the 
data was analysed for descriptive statistics. For example, muscularis 
propria was not included in biopsy of three patients. 
Two features were evaluated in H&E, the absence of ganglion cells 
in submucosa and muscularis propria, and the presence of nerve bundle 
hypertrophy in these regions, for the diagnosis of HD. Though former is 
the pathognomonic feature for HD, the latter being a positive finding 
serves as a very useful additional feature for diagnosis. Of the 30 samples 
in our study, 5 cases showed ganglion cells in both the ganglionic and 
aganglionic segments, hence diagnosed as NHD. Of the remaining 25 
samples of submucosa and 22 samples of muscularis propria, 19 in each 
layer showed nerve hypertrophy. Based on this the sensitivity, specificity 
and PPV for nerve bundle hypertrophy in diagnosing HD was 86.4%, 
100% and 100% respectively (Table 6, 6A). The presence of hypertrophic 
nerve bundle was a strong positive factor for diagnosis while its absence 
did not accurately exclude HD. 
Clinical short segment (SHD) disease showed absence of 
hypertrophic nerve bundles in around 15% of cases (Table 7) while the 
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extended segment disease (LHD/TCA), showed absence in 50%.  This is 
similar to findings of Narayanan SK et al, who recorded lesser incidence 
(20%) of nerve bundle hypertrophy in the extended segment HD in a 
study of ninety two HD proved cases [71]. 
Calretinin IHC, similar to H&E, was also used to evaluate two 
features, viz., the immunoreactivity of ganglion cells in submucosa and 
muscularis propria, and immunoreactivity of intrinsic nerve fibres. When 
Calretinin staining was done, all the five cases with presence of ganglion 
cell in H&E also stained positive for Calretinin and showed 
immunoreactivity in nerve fibres as well, thus confirming the diagnosis of 
non-HD. Of 25 cases diagnosed as HD by ganglion cell negativity using 
IHC, three cases (12% cases) showed immunoreactivity in nerve fibres. 
However, the pattern of staining was found to be faint and punctate (Fig 
21A&B) which was distinctly different from confluent, dark, granular 
immunostaining of normal nerve fibres. This showed that nerve fibres can 
show immunoreactivity falsely in cases of HD. Hiradfar et al [103] 
similarly showed false positive staining of nerve fibres in 2/ 30 cases 
(6.7%) of HD patients. Kapur et al [81] also recorded nerve fibre 
immunoreactivity in submucosal nerve fibres in the few of their HD 
patients. No explanation could be provided for this pattern by the authors. 
Guinard-Samuel et al [102] explained that this positive staining of some 
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nerve fibers could indicate the beginning of transitional zone. The nerve 
fibre immunoreactivity in HD had sensitivity and specificity of 88% and 
100% respectively (Table 8). 
H&E was compared with Calretinin IHC to find if IHC would fare 
better in diagnosing HD. Submucosa was available for evaluation on 30 
samples and muscularis propria in 27 samples. Of these 57 observations, 
Observer 1 recorded 13 (23%) equivocal findings and observer 2 
recorded 3(5%) equivocal findings (Table 9 and 10). There was no 
suspicious or equivocal finding using Calretinin IHC. Our findings 
showed a 100% and 90% sensitivity of H&E for Observer 1 and observer 
2 respectively. However the sensitivity was poor. 
Interobserver agreement was assessed between observer 1, a non 
experienced pathologist and observer 2, an experienced pathologist. The 
Cohen’s kappa assessment showed a moderate agreement for H&E of 
0.574(kappa) (95%CI 0.36-0.78) (Page no 71).  However, observations of 
Calretinin IHC stained slides showed no discordance among the 30 cases.  
The kappa value of IHC showed a perfect agreement (Kappa=1, p<0.05) 
(Table 11 and 12). This is similar to the findings of Anbardar MH et al 
[109]. They showed interobserver agreement (Kappa) of 0.97 using 
Calretinin IHC in their study on 82 paraffin blocks. 
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Based on their observations, both the evaluators were required to 
give a final diagnosis of HD or non HD for all the cases. There was 
equivocal diagnosis in four cases by Observer 1 and for one case by 
observer 2 using H&E. Five cases were diagnosed as NHD and rest as 
HD by both observers. Calretinin confirmed all the five NHD diagnosis 
giving a specificity of 100%. Calretinin IHC confirmed all the suspicious 
diagnosis as HD. This showed that additional 13.3% (4 cases of 30) could 
be diagnosed when Calretinin IHC is used over H&E. This improved 
diagnosis is concordant with the study by Guinard et al, where of the 131 
cases studied 12 additional cases which were equivocal by H&E could be 
diagnosed as HD with Calretinin IHC [103]. Kannaiyan et al in their study 
of 60 cases also showed all 15 cases with equivocal diagnosis by H&E 
could be diagnosed with accuracy with Calretinin IHC [105]. 
There are few limitations to our study. Our data shows Calretinin is 
a good adjunct to H&E in the diagnosis of HD. But this does not obviate 
the need for H&E and Calretinin IHC is still an additional investigation 
that would be required to improve the diagnosis. The specificity of H&E 
could not be calculated due to equivocal diagnosis in few cases. We could 
not get all the layers of bowel in all 30 patients, reducing the robustness 
of our descriptive statistics. 
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SUMMARY 
 This retro-prospective study was done on full thickness rectal 
biopsy and resected specimens of patients with suspected 
Hirschsprung’s disease (HD).  
 The study was conducted at Coimbatore Medical College Hospital, 
Coimbatore and the study period being August 2016 – March 2018. 
 The study was done to compare the diagnostic sensitivity of H&E 
and Calretinin IHC in suspected cases of HD and the staining 
pattern of ganglion cells in various layers of bowel tissue. 
Interobserver concordance in diagnosis was also evaluated between 
two pathologists for both H&E and IHC. 
 Total of 30 cases of clinically suspected HD were taken for study. 
A sample from ganglionic and aganglionic segment were analyzed 
for each patient for the presence of ganglion cells and nerve bundle 
hypertrophy by H&E. Similarly, Calretinin was used to assess the 
ganglion cells and nerve fibre immunoreactivity in all the bowel 
layers. 
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 Both H&E and Calretinin assessment was done by two 
pathologists, one experienced (observer 2) and another in-training 
pathologist (observer 1), independently, blinded from each other. 
 Descriptive statistics was used to assess the demographic 
parameters and diagnostic performance of Calretinin IHC. Cohen’s 
kappa was used to calculate the interobserver agreement. 
Sensitivity and specificity analysis was done wherever appropriate. 
 Most patients were neonates. 87% had short segment involvement. 
73.3% and 26.7% specimens were full thickness biopsy and 
resection specimens respectively.  
 Of the 30 specimens, 5 were diagnosed as Non-HD based on H&E 
and confirmed with Calretinin IHC. Of the 25 remaining patients, 
suspicious diagnosis was reported in four patients by Observer 1 
and one patient by Observer 2. However, both pathologists could 
provide a definitive diagnosis of HD with Calretinin IHC in these 
cases. Hence, Calretinin IHC improved the sensitivity by 13.3% 
over H&E. 
 There were around 13.8% equivocal observations by H&E for 
detecting ganglion cells, while no equivocal observations with 
Calretinin IHC. 
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 In H&E, nerve fibre hypertrophy as a predictor of HD showed a 
sensitivity and specificity of 86.4% and 100% respectively. Nerve 
immunoreactivity in IHC showed a sensitivity and specificity of 
88% and 100% respectively. 
 The Cohen’s kappa assessment showed a moderate agreement for 
H&E of 0.574 (95%CI: 0.36-0.78), while IHC showed a perfect 
agreement of 1. 
 Our findings suggest that Calretinin improves the sensitivity of 
diagnosing HD by 13% over H&E by providing confirmatory 
diagnosis for patients with equivocal findings. 
 The agreement in diagnosing HD by an experienced and non-
experienced pathologist also significantly improved (p<0.05) with 
the use of Calretinin IHC.(kappa = 0.574 for H&E and kappa=1 for 
IHC).  
93 
 
CONCLUSION 
Our present study shows that Calretinin can be a useful adjunct to 
H&E in the diagnosis of HD, improving the diagnostic sensitivity 
(diagnose more cases), accuracy (confirm suspicious cases) and precision 
(reduce interobserver variation).  
There was no interobserver variation between experienced and 
non-experienced pathologist in diagnosing HD using Calretinin IHC 
unlike H&E. So, Calretinin could prove to be a very useful adjunct 
marker in improving diagnostic accuracy in centres with lesser 
experience.  
Calretinin IHC adds to the cost of diagnosis of HD. This additional 
cost could be justified by the improvement in sensitivity and accuracy 
which would save the patient from morbidity and expenses of a second 
look surgery. 
There was 12% false positive immunoreactivity of nerve fibres to 
Calretinin IHC. Though the pattern of reactivity was different from that 
of non-HD cases, this warrants further study. 
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SM MP SM MP SM MP SM MP SM MP LP MM SM MP SM MP LP MM SM MP
1 2886/16 28 Male SHD resection Pos E Pos Neg Pos Pos Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
2 3105/16 7 Female SHD Biopsy Neg E Neg Pos Pos Pos Neg Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
3 3354/16 30 Male SHD Biopsy Neg Neg Pos Pos Neg Pos Neg Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
4 3774/16 7 Male SHD Biopsy E E Neg Pos Pos E Neg Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
5 4033/16 15 Male SHD Biopsy Neg E Pos Pos Pos Pos Neg Pos Neg Neg Neg Neg Neg Neg Pos Pos Neg Pos Pos Pos
6 0333/17 2 Female SHD Biopsy E Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
7 0399/17 365 Male SHD resection Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
8 0445/17 154 Female LHD resection Neg Neg Neg Pos Neg Pos Neg Neg Neg Neg Neg Pos Neg Neg Pos Pos Pos Pos Pos Pos
9 0563/17 5 Male SHD Biopsy Neg Absent Pos Absent Absent E Absent Pos Neg Absent Neg Absent Neg Absent Absent Pos Absent Absent Absent Pos
10 0899/17 1460 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
11 1237/17 3650 Female SHD resection Neg Neg Pos Pos Pos Pos Neg Pos Neg Neg Neg Pos Neg Neg Pos Pos Pos Pos Pos Pos
12 1980/17 42 Male SHD Biopsy E Pos Neg Neg Pos Pos Neg Neg Pos Pos Absent Absent Pos Pos Pos Pos Pos Pos Pos Pos
13 2215/17 2 Male SHD Biopsy E Neg Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
14 2216/17 3650 Female SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
15 2344/17 7 Male SHD Biopsy E Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
16 2345/17 184 Female SHD resection Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
17 2469/17 7 Female LHD Biopsy Neg E Neg Pos Pos Pos Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
18 2487/17 4 Male SHD Biopsy Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
19 3239/17 215 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
20 3300/17 3 Male SHD Biopsy Neg Neg Neg Neg E Absent Neg Absent Neg Neg Neg Neg Neg Neg Pos Absent Pos Pos Pos Absent
21 3352/17 4 Male SHD Biopsy Neg Neg Neg Pos Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
22 3761/17 2 Male SHD Biopsy E Pos Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
23 3848/17 122 Male SHD resection E E Pos Pos Pos Pos Neg Neg Neg Neg Neg Pos Neg Neg Pos Pos Pos Pos Pos Pos
24 3989/17 365 Male SHD Biopsy Pos Absent Neg Absent Pos Absent Neg Absent Neg Absent Pos Pos Pos Absent Pos Absent Pos Pos Pos Absent
25 4067/17 365 Male SHD resection Neg Neg Pos Pos Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
26 4385/17 6 Male TCA Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos
27 0062/18 122 Female SHD Biopsy Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
28 0192/18 365 Male SHD Biopsy Neg Absent Pos Absent Pos Pos Neg Neg Neg Absent Neg Neg Neg Absent Pos Pos Pos Pos Pos Pos
29 0212/18 60 Male LHD resection Neg Neg Pos Pos Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
30 0920/18 731 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Pos Pos Pos
SHD= Short Segment Hirschprung disease E= equivocal SM: Submucosa HT= Hypertrophic nerve bundles
LHD= Long Segment Hirschprung disease Absent= sample unavailable MP: Muscularis propria
TCA= Total colonic Aganglionosis Pos= positive LP:Laminapropria
Neg= Negative MM: muscularis mucosa
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SM MP SM MP SM MP SM MP SM MP LP MM SM MP SM MP LP MM SM MP
1 2886/16 28 Male SHD resection E Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 3
2 3105/16 7 Female SHD Biopsy Neg Neg Neg Pos Neg E Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
3 3354/16 30 Male SHD Biopsy Neg Neg Pos Pos E Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
4 3774/16 7 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
5 4033/16 15 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Pos Pos Pos 2
6 0333/17 2 Female SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
7 0399/17 365 Male SHD resection Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 2
8 0445/17 154 Female LHD resection Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos 3
9 0563/17 5 Male SHD Biopsy Neg Absent Neg Absent Absent Neg Absent Neg Neg Absent Neg Neg Neg Absent Absent Neg Absent Absent Absent Neg Neg
10 0899/17 1460 Male SHD Biopsy Neg Neg Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
11 1237/17 3650 Female SHD resection Neg Neg Pos Pos Pos Pos Pos Pos Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos Pos 3
12 1980/17 42 Male SHD Biopsy Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Absent Absent Pos Pos Pos Pos Pos Pos Pos Pos 3
13 2215/17 2 Male SHD Biopsy Neg Neg Pos Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
14 2216/17 3650 Female SHD Biopsy E Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
15 2344/17 7 Male SHD Biopsy Neg Neg Pos Pos E Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 2
16 2345/17 184 Female SHD resection Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
17 2469/17 7 Female LHD Biopsy Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
18 2487/17 4 Male SHD Biopsy Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 3
19 3239/17 215 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
20 3300/17 3 Male SHD Biopsy Neg Neg Pos Neg Neg Absent Neg Absent Neg Neg Pos Neg Pos Neg Pos Absent Pos Pos Pos Absent 2
21 3352/17 4 Male SHD Biopsy Neg Neg Pos Pos Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
22 3761/17 2 Male SHD Biopsy E Neg Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 3
23 3848/17 122 Male SHD resection Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos 3
24 3989/17 365 Male SHD Biopsy Neg Absent Pos Absent Pos Absent Neg Absent Neg Absent Neg Neg Neg Absent Pos Absent Pos Pos Pos Absent 3
25 4067/17 365 Male SHD resection Neg Neg Pos Pos Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
26 4385/17 6 Male TCA Biopsy Neg Neg Pos Pos E Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Pos Pos Pos Pos 2
27 0062/18 122 Female SHD Biopsy Pos Pos Neg Neg Pos Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 2
28 0192/18 365 Male SHD Biopsy Neg Absent Pos Absent Pos Pos Neg Neg Neg Absent Neg Neg Neg Absent Pos Pos Pos Pos Pos Pos 3
29 0212/18 60 Male LHD resection Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg
30 0920/18 731 Male SHD Biopsy Neg Neg Pos Pos Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Pos Pos Pos 2
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